文献速递白血病

酪氨酸激酶抑制剂停药后慢性髓性白血病患者的健康相关生活质量与症状:EURO-SKI试验结果

Health-related quality of life and symptoms of chronic myeloid leukemia patients after discontinuation of tyrosine kinase inhibitors: results from the EURO-SKI Trial.
PubMed 文献 · Leukemia · 2024-07-10

EURO-SKI试验评估慢性髓性白血病患者停用酪氨酸激酶抑制剂后的健康相关生活质量和症状,纳入11个欧洲国家728例基线患者,686例(94%)完成评估。中位停药年龄60岁。生活质量和症状轨迹因年龄组而异,年轻患者获益最大,60岁及以上患者改善有限。

要点

  • 年轻患者停用TKI后健康相关生活质量获益最大。
  • 60岁及以上患者多个生活质量和症状领域改善有限。
  • 医生可告知年轻患者停药后可能获得有价值的生活质量获益。

核心结论

  • 停用TKI后健康相关生活质量和症状轨迹因年龄组而异,年轻患者获益最大,60岁及以上患者改善有限。
  • 作者建议在考虑停用TKI时,医生可告知年轻患者可能获得有价值的生活质量获益。
  • 作者认为在60岁及以上患者中,需进一步研究无治疗缓解与最低有效剂量策略的价值比较。

研究设计与样本

  • EURO-SKI试验,纳入接受TKI治疗至少3年且达到MR4至少1年的慢性髓性白血病患者,来自11个欧洲国家。
  • 使用EORTC QLQ-C30和FACIT-疲劳问卷评估健康相关生活质量和疲劳。
  • 728例患者进行基线评估,686例(94%)完成健康相关生活质量评估;中位停药年龄60岁。
  • 患者按年龄分为18-39岁、40-59岁、60-69岁和≥70岁组。

主要发现

  • 健康相关生活质量和症状轨迹可能因特定年龄组而异,年轻患者获益最大。
  • 60岁及以上患者在多个健康相关生活质量和症状领域改善有限。

临床怎么用

  • 作者建议在考虑停用TKI时,医生可告知年轻患者可能获得有价值的生活质量获益。
  • 作者认为在60岁及以上患者中,需进一步研究无治疗缓解与最低有效剂量策略的价值比较。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Limited data is available on the health-related quality of life (HRQoL) and symptoms of patients with chronic myeloid leukemia (CML) who are in treatment-free remission (TFR). We herein report HRQoL results from the EURO-SKI trial. Patients who had been on tyrosine kinase inhibitors (TKIs) therapy for at least 3 years and achieved MR4 for at least 1 year were enrolled from 11 European countries, and the EORTC QLQ-C30 and the FACIT-Fatigue questionnaires were used to assess HRQoL and fatigue respectively. Patients were categorized into the following age groups: 18-39, 40-59, 60-69 and ≥70 years. Of 728 patients evaluated at baseline, 686 (94%) completed HRQoL assessments. The median age at TKI discontinuation was 60 years. Our findings indicate that HRQoL and symptom trajectories may vary depending on specific age groups, with younger patients benefiting the most. Improvements in patients aged 60 years or older were marginal across several HRQoL and symptom domains. At the time of considering TKI discontinuation, physicians could inform younger patients that they may expect valuable HRQoL benefits. Considering the marginal improvements observed in patients aged 60 years or above, it may be important to further investigate the value of TFR compared to a lowest effective dose approach in this older group of patients.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. Efficace F, Mahon FX, Richter J, et al. Health-related quality of life and symptoms of chronic myeloid leukemia patients after discontinuation of tyrosine kinase inhibitors: results from the EURO-SKI Trial. Leukemia. 2024. PMID: 38987274. doi:10.1038/s41375-024-02341-4

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。